HK1130009A1 - Fgf-peceptor agonist dimeric compounds fgf - Google Patents

Fgf-peceptor agonist dimeric compounds fgf

Info

Publication number
HK1130009A1
HK1130009A1 HK09108015.5A HK09108015A HK1130009A1 HK 1130009 A1 HK1130009 A1 HK 1130009A1 HK 09108015 A HK09108015 A HK 09108015A HK 1130009 A1 HK1130009 A1 HK 1130009A1
Authority
HK
Hong Kong
Prior art keywords
fgf
peceptor
dimeric compounds
agonist
agonist dimeric
Prior art date
Application number
HK09108015.5A
Other languages
English (en)
Inventor
Bono Francoise
Guillo Nathalie
Maffrand Jean-Pierre
Fons Pierre
Olsen Jacob-Alsboek
Anne-Archard Gilles
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1130009A1 publication Critical patent/HK1130009A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK09108015.5A 2006-01-13 2009-09-02 Fgf-peceptor agonist dimeric compounds fgf HK1130009A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600317A FR2896247B1 (fr) 2006-01-13 2006-01-13 Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
PCT/FR2007/000051 WO2007080325A1 (fr) 2006-01-13 2007-01-12 Composes dimeres agonistes des recepteurs des fgfs

Publications (1)

Publication Number Publication Date
HK1130009A1 true HK1130009A1 (en) 2009-12-18

Family

ID=36808846

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09108015.5A HK1130009A1 (en) 2006-01-13 2009-09-02 Fgf-peceptor agonist dimeric compounds fgf

Country Status (37)

Country Link
US (1) US9120819B2 (ko)
EP (1) EP2018165B1 (ko)
JP (1) JP5286088B2 (ko)
KR (1) KR101378220B1 (ko)
CN (1) CN101384258B (ko)
AR (1) AR059001A1 (ko)
AT (1) ATE505188T1 (ko)
AU (1) AU2007204252B2 (ko)
BR (1) BRPI0707132A2 (ko)
CA (1) CA2633057C (ko)
CR (1) CR10097A (ko)
CY (1) CY1111688T1 (ko)
DE (1) DE602007013889D1 (ko)
DK (1) DK2018165T3 (ko)
EA (1) EA015046B1 (ko)
EC (1) ECSP088592A (ko)
ES (1) ES2364857T3 (ko)
FR (1) FR2896247B1 (ko)
HK (1) HK1130009A1 (ko)
HN (1) HN2008001067A (ko)
HR (1) HRP20110514T1 (ko)
IL (1) IL192403A (ko)
JO (1) JO2659B1 (ko)
MA (1) MA30214B1 (ko)
MX (1) MX2008009010A (ko)
NO (1) NO20083406L (ko)
NZ (1) NZ569631A (ko)
PE (1) PE20071115A1 (ko)
PL (1) PL2018165T3 (ko)
PT (1) PT2018165E (ko)
RS (1) RS51872B (ko)
SI (1) SI2018165T1 (ko)
TN (1) TNSN08250A1 (ko)
TW (1) TWI386408B (ko)
UA (1) UA95469C2 (ko)
WO (1) WO2007080325A1 (ko)
ZA (1) ZA200806547B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2883286B1 (fr) * 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
EP2270043A1 (en) 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
FR2962437B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
US8901341B2 (en) 2011-02-11 2014-12-02 Bezwada Biomedical, Llc Amino acid derivatives and absorbable polymers therefrom
WO2012167261A2 (en) 2011-06-03 2012-12-06 Yale University Compositions and methods for treating and preventing neointimal stenosis
FR2982261B1 (fr) * 2011-11-04 2014-06-13 Galderma Res & Dev Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique
FR2985257B1 (fr) * 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
FR2985258A1 (fr) * 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
FR2985185B1 (fr) * 2012-01-04 2013-12-27 Sanofi Sa Utilisation en therapeutique de derives d'imidazopyridine
AU2014233520B2 (en) * 2013-03-15 2019-02-21 The Regents Of The University Of California Modulators of the eIF2alpha pathway
JP2016520060A (ja) * 2013-05-06 2016-07-11 アンドリュー・ビー・ブッシュ invivoでの抗体産生および液性免疫のFGF調節
JP6957468B2 (ja) 2015-12-11 2021-11-02 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 最適化された患者特異的組織操作血管移植片のためのシステムおよび方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
JP5599543B2 (ja) 2002-05-07 2014-10-01 ノヴォ ノルディスク アー/エス 単量体インスリン及びアシル化インスリンを含む可溶性製剤
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
JO2659B1 (en) 2012-06-17
KR20090006060A (ko) 2009-01-14
JP5286088B2 (ja) 2013-09-11
CR10097A (es) 2008-10-29
WO2007080325A8 (fr) 2008-10-23
KR101378220B1 (ko) 2014-03-27
PT2018165E (pt) 2011-07-14
BRPI0707132A2 (pt) 2011-04-19
MA30214B1 (fr) 2009-02-02
CY1111688T1 (el) 2015-10-07
CN101384258A (zh) 2009-03-11
ATE505188T1 (de) 2011-04-15
US20090069368A1 (en) 2009-03-12
MX2008009010A (es) 2008-09-25
CN101384258B (zh) 2013-06-26
SI2018165T1 (sl) 2011-08-31
ECSP088592A (es) 2008-08-29
TWI386408B (zh) 2013-02-21
UA95469C2 (ru) 2011-08-10
EA015046B1 (ru) 2011-04-29
PL2018165T3 (pl) 2011-09-30
EA200870167A1 (ru) 2009-12-30
ZA200806547B (en) 2009-12-30
AU2007204252B2 (en) 2012-05-24
US9120819B2 (en) 2015-09-01
FR2896247B1 (fr) 2008-02-29
IL192403A (en) 2012-10-31
JP2009523160A (ja) 2009-06-18
CA2633057C (fr) 2014-10-21
TNSN08250A1 (en) 2009-10-30
FR2896247A1 (fr) 2007-07-20
CA2633057A1 (fr) 2007-07-19
AU2007204252A1 (en) 2007-07-19
WO2007080325A1 (fr) 2007-07-19
PE20071115A1 (es) 2007-12-14
DE602007013889D1 (de) 2011-05-26
AR059001A1 (es) 2008-03-05
DK2018165T3 (da) 2011-08-01
TW200738708A (en) 2007-10-16
HN2008001067A (es) 2011-01-24
EP2018165A1 (fr) 2009-01-28
NZ569631A (en) 2011-04-29
RS51872B (en) 2012-02-29
ES2364857T3 (es) 2011-09-15
IL192403A0 (en) 2008-12-29
NO20083406L (no) 2008-10-13
EP2018165B1 (fr) 2011-04-13
HRP20110514T1 (hr) 2011-08-31

Similar Documents

Publication Publication Date Title
HK1130009A1 (en) Fgf-peceptor agonist dimeric compounds fgf
MX2010001575A (es) Derivados de 1,2-diamido-etileno como antagonistas de orexina.
MX2009009690A (es) Derivados de tiazolidina como antagonistas del receptor de orexina.
EA200801758A1 (ru) Лекарственные формы, устойчивые к самовольному изменению
PL2069332T3 (pl) Związki azetydynowe jako antagoniści receptorów oreksynowych
ATE483707T1 (de) 2-cyclopropylthiazolderivate
HK1149950A1 (en) Novel compositions and related methods, coatings, and articles
MY153921A (en) Aminopyrazole derivatives
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
ATE447568T1 (de) Neue pyrinderivate
IL201973A0 (en) 3,3-spiroindolinone derivatives
MX356658B (es) Compuestos dímeros agonistas de los receptores de los fgf (fgfr), su proceso de preparación y su uso terapéutico.
ZA201001797B (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
PL1981826T5 (pl) Płyta budowlana
GB2461659A (en) Structured compositions comprising a clay
ZA201008657B (en) 4,5-dihydro-oxazol-2-yl derivatives
ZA201002217B (en) 1,3-dihydroisoindole derivatives
SE0800742L (sv) Vikttäcke
IT1396622B1 (it) Pannello modulare autoportante, particolarmente per arredi d'ufficio
UA96476C2 (ru) Фармацевтические композиции, которые содержат ирбесартан
IL201444A0 (en) New 4, 8 - diphenyl - polyazanaphthalene derivatives
CY1110787T1 (el) Νεα μορφινικα παραγωγα
AU2008904506A0 (en) G.Cyl 500.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170112